Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT).
Jolliffe, David A Holt, Hayley Greenig, Matthew Talaei, Mohammad Perdek, Natalia Pfeffer, Paul Vivaldi, Giulia Maltby, Sheena Symons, Jane Barlow, Nicola L
Jolliffe, David A
Holt, Hayley
Greenig, Matthew
Talaei, Mohammad
Perdek, Natalia
Pfeffer, Paul
Vivaldi, Giulia
Maltby, Sheena
Symons, Jane
Barlow, Nicola L
Citations
Altmetric:
Affiliation
Queen Mary University of London; University of Birmingham; Swansea University Medical School; Sandwell and West Birmingham NHS Trust
Other Contributors
Publication date
2022-09-07
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Objective: To determine the effect of population level implementation of a test-and-treat approach to correction of suboptimal vitamin D status (25-hydroxyvitamin D (25(OH)D) <75 nmol/L) on risk of all cause acute respiratory tract infection and covid 19.
Design: Phase 3 open label randomised controlled trial.
Setting: United Kingdom.
Participants: 6200 people aged ≥16 years who were not taking vitamin D supplements at baseline.
Interventions: Offer of a postal finger prick test of blood 25(OH)D concentration with provision of a six month supply of lower dose vitamin D (800 IU/day, n=1550) or higher dose vitamin D (3200 IU/day, n=1550) to those with blood 25(OH)D concentration <75 nmol/L, compared with no offer of testing or supplementation (n=3100). Follow-up was for six months.
Main outcome measures: The primary outcome was the proportion of participants with at least one swab test or doctor confirmed acute respiratory tract infection of any cause. A secondary outcome was the proportion of participants with swab test confirmed covid-19. Logistic regression was used to calculate odds ratios and associated 95% confidence intervals. The primary analysis was conducted by intention to treat.
Results: Of 3100 participants offered a vitamin D test, 2958 (95.4%) accepted and 2674 (86.3%) had 25(OH)D concentrations <75 nmol/L and received vitamin D supplements (n=1328 lower dose, n=1346 higher dose). Compared with 136/2949 (4.6%) participants in the no offer group, at least one acute respiratory tract infection of any cause occurred in 87/1515 (5.7%) in the lower dose group (odds ratio 1.26, 95% confidence interval 0.96 to 1.66) and 76/1515 (5.0%) in the higher dose group (1.09, 0.82 to 1.46). Compared with 78/2949 (2.6%) participants in the no offer group, 55/1515 (3.6%) developed covid-19 in the lower dose group (1.39, 0.98 to 1.97) and 45/1515 (3.0%) in the higher dose group (1.13, 0.78 to 1.63).
Conclusions: Among people aged 16 years and older with a high baseline prevalence of suboptimal vitamin D status, implementation of a population level test-and-treat approach to vitamin D supplementation was not associated with a reduction in risk of all cause acute respiratory tract infection or covid-19.
Citation
Jolliffe, D. A., Holt, H., Greenig, M., Talaei, M., Perdek, N., Pfeffer, P., Vivaldi, G., Maltby, S., Symons, J., Barlow, N. L., Normandale, A., Garcha, R., Richter, A. G., Faustini, S. E., Orton, C., Ford, D., Lyons, R. A., Davies, G. A., Kee, F., Griffiths, C. J., … Martineau, A. R. (2022). Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). BMJ (Clinical research ed.), 378, e071230. https://doi.org/10.1136/bmj-2022-071230
Type
Article